Abstract:The diagnosis of Myelodysplastic syndromes (MDS) is frequently challenging, especially in terms of the distinction from the other non-neoplastic causes of cytopenia. Currently, it is based on the presence of peripheral blood cytopenias, peripheral blood and bone marrow dysplasia/blasts, and clonal cytogenetic abnormalities, but MDS diagnostic features are polymorphic and non-specific. We investigated the utility of complete blood count (CBC) and research parameters (RUO) from the analyzer BC 6800 Plus (Mindray Diagnostics) to discriminate MDS-related cytopenia. Methods: 100 samples from healthy individuals were used to establish the values of research parameters in normal subjects. A retrospective study was conducted including 66 patients diagnosed with MDS, 90 cytopenic patients due to other diseases (cancer patients receiving therapy, aplastic anemia, other hematological malignancies) and 50 with macrocytic anemia. The Wilcoxon test was applied to detect statistical differences among the groups of patients, considering p < 0.05 significant. The diagnostic performance of the RUO parameters for discriminating MDS among cytopenias was evaluated using receiver operating characteristic (ROC) curve analysis. Amultivariable logistic regression model was performed to identify the potential predictors for having MDS. The area under curve (AUC) and the Hosmer–Lemeshow test of the model were assessed. The performance of the model was verified in a prospective study including 224 cytopenic patients (validation group). Results: In the MDS group, the mean cell volume (MCV), percentage of macrocytic red cells (MAC), red cell distribution width (RDW) and immature platelets fraction (IPF) had increased values compared to the cytopenic and normal patients, while platelets, red and white cell counts, Neu X (related to the cytoplasmic complexity of neutrophils), Neu Y (related to nucleic acid content) and Neu Z (related to cell size) were lower (p 0.80; MAC, RDW and IPF AUC > 0.76. The multivariable model demonstrated that Neu X and Neu Y could be used in the recognition of MDS, AUC 0.88. In the validation group, 89.0% of the MDS patients were well classified. Conclusion: MDS are common malignant disorders with a poor prognosis, and early diagnosis is warranted for optimal benefit from treatment. RUO gain insights to detect dysplasia of MDS and could be used in the differential diagnosis of MDS from cytopenias of other etiologies.

Side scatter ratio of the CD105-positive and CD105-negative red blood cell fractions is useful for the detection of low-grade myelodysplastic neoplasms by flow cytometry

[Application of Two-parameter Scoring System Based on CD105 and CD117 in MDS Diagnosis].

[Karyotype Analysis of 283 Cases of Myelodysplastic Syndrome].

Analysis of the Karyotype Abnormalities and Its Prognostic in 298 Patients with Myelodysplastic Syndrome

Complete Blood Counts and Research Parameters in the Detection of Myelodysplastic Syndromes

[Role of Flow Cytometry in the Diagnosis of Chronic Myeloid Leukemia].

[The Value of Flow Cytometry for the Differential Diagnosis Between Refractory Cytopenia with Multiple Dysplasia and Aplastic Anemia].

Peripheral blood circulating CD34+ cell count in patients with MDS-RA/RARS/RCMD

Flow cytometry in the differential diagnosis of myelodysplastic neoplasm with low blasts and cytopenia of other causes

Value Of Flow Cytometry For Differential Diagnosis Between Refractory Cytopenia With Multilineage Dysplasia And Aplastic Anemia

Expression and significance of CD34, CD117 on bone marrow mononuclear cells of patients with myelodysplastic syndrome

Characteristics of bone marrow cell dysplasia and its effectiveness in diagnosing myelodysplastic syndrome

The ratio of bone marrow myeloid progenitor cell proportion to mature lymphocytes proportion can effectively differentiate aplastic anemia and hypoplastic myelodysplastic syndrome and evaluate the quality of bone marrow aspirates

Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study

Clinical study of the number of circulating CD34~+ cells in the peripheral blood from patients with myelodysplastic syndromes

Performance of Automatic Blood Cell Analysis Parameters for Differential Diagnosis of Myelodysplastic Syndromes and Aplastic Anemia

Research use only and cell population data items obtained from the Beckman Coulter DxH800 automated hematology analyzer are useful in discriminating MDS patients from those with cytopenia without MDS

Biological implications of circulating CD34(+) cells in myelodysplastic syndromes

Bone marrow S-phase is Associated with Risk assessment and Shows Differential Correlation with levels of CD34+ Blasts and CD16- Granulocytes in Patients with Myelodysplastic syndromes

Combination of NeuX and NeuZ can predict neutrophil dysplasia features of myelodysplastic neoplasms in peripheral blood

The Immunophenotypic Analysis of CD7+ And(or)cd56+ Acute Myeloid Leukemic Stem Cells and Its Applications in Minimal Residual Disease Detection